Skip to main content
Luoxin Pharmaceuticals Group Stock Co., Ltd. logo

Luoxin Pharmaceuticals Group Stock Co., Ltd. — Investor Relations & Filings

Ticker · 002793 ISIN · CNE1000026S7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,601 across all filing types
Latest filing 2026-02-13 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002793

About Luoxin Pharmaceuticals Group Stock Co., Ltd.

https://www.luoxin.cn

Luoxin Pharmaceuticals Group Stock Co., Ltd. focuses on the research, development, manufacturing, and distribution of diverse medicinal products. The company specializes in therapeutic areas including digestive health, respiratory medicine, anti-infectives, and oncology. Its portfolio includes various formulations such as injections, tablets, and capsules, with a notable emphasis on proton pump inhibitors and respiratory treatments. Luoxin operates a vertically integrated model, producing both active pharmaceutical ingredients (APIs) and finished dosage forms. The organization emphasizes innovation through dedicated R&D facilities to develop high-quality healthcare solutions. Its operations are supported by a comprehensive supply chain and manufacturing infrastructure designed to adhere to international quality standards, serving broad market segments with a focus on clinical efficacy and patient accessibility.

Recent filings

Filing Released Lang Actions
资产评估报告
Regulatory Filings
2026-02-13 Chinese
审计报告
Regulatory Filings
2026-02-13 Chinese
第六届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the company's sixth board of directors' second meeting. It includes details about the meeting date, attendance, and voting results on a specific agenda item related to the acquisition of minority shareholder equity in a subsidiary and related party transactions. The document does not contain full financial statements or detailed financial analysis but focuses on board decisions and meeting outcomes. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting results announcement for a shareholder meeting but rather a board meeting resolution announcement. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board decisions, confirming this classification.
2026-02-13 Chinese
关于受让控股子公司少数股东股权暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the acquisition of minority equity interests in a controlling subsidiary by the company, involving a related party transaction. It includes extensive information about the transaction terms, parties involved, financial data, valuation and assessment reports, board and independent director approvals, and legal compliance. The content focuses on a capital transaction affecting the company's shareholding structure in a subsidiary, with no indication of it being a full annual or interim financial report, earnings release, or other report types. The document is not a simple announcement of a report publication but a substantive disclosure of a capital/financing update related to shareholding changes in a subsidiary. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-02-13 Chinese
2025年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2025年度业绩预告 (2025 Annual Performance Forecast) issued by 罗欣药业集团股份有限公司. It provides an earnings forecast for the full fiscal year 2025, including expected net profit ranges and explanations for performance changes. It explicitly states that the financial data is preliminary, unaudited, and subject to final audited results in the 2025 Annual Report. The document length is 1512 characters, which is relatively short and primarily serves as an earnings forecast announcement rather than a full financial report. It does not contain actual audited financial statements or detailed financial analysis. Therefore, it fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results (key highlights only). FY 2025
2026-01-30 Chinese
第六届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the first meeting of the sixth board of directors of Luoxin Pharmaceutical Group Co., Ltd. It includes election and appointment of the chairman, board committees, general manager, financial officer, board secretary, securities affairs representative, and internal audit head. It also provides biographical details of these appointees. The content focuses on changes and appointments in the company's board and senior management, with voting results and compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication mentioned. The document is not a report itself but an official announcement of board and management changes.
2026-01-29 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.